Healthcare entity
Royal Bank of Canada is most often covered alongside Citigroup, which appears in 1 of these 2 stories. That works out to roughly 0.4 stories per week across a 39-day span. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.4 for the same window.
Last mentioned: 19h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Royal Bank of Canada is most often covered alongside Citigroup, which appears in 1 of these 2 stories. That works out to roughly 0.4 stories per week across a 39-day span. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.4 for the same window. Their average consequence score of 5 runs below the beat's 5.9 for that window. The clearest coverage concentration is funding: 1 of 2 stories, with the rest divided among 1 other category. Royal Bank of Canada appears in 2 tracked Healthcare stories published from July 10, 2026 through August 17, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 380 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Royal Bank of Canada. Shared-story counts are live from our verified record — not editorial picks.
NBRHC Foundation recognizes $60,000 grant
North Bay Regional Health Centre Foundation announces RBC Foundation's $60,000 grant to improve accessibility at Mishkikiwan.
Community Spaces Grant program launches
RBC Foundation launches a grant program to fund accessible and environmentally sustainable community spaces across Canada.
RBC Foundation's $60,000 Community Spaces Grant will fund wheelchair and stretcher access to Mishkikiwan, North Bay Regional Health Centre's outdoor ceremonial grounds, strengthening culturally safe Indigenous care.
Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
Royal Bank of Canada is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
